Revolution Medicines, Inc.

RVMD

$210.87

+0.78%

N/A+$1.64

Healthcare

Biotechnology

NASDAQ

Active Trading

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel ...

Key Metrics of RVMD

Snapshot

Latest / TTM · 6 periods

Market Cap

$44.83B

ROCE

-41.0%

EV / EBITDA

-26.34x

+16.3% YoY

FCF Yield

-3.5%

+2.5% YoY

Cash Conversion Cycle

-3493.9d

Current Ratio

11.38

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$1.83B	$1.92B	$3.25B	$7.34B	$15.14B	$44.83B
Enterprise ValueCompany value including debt and cash adjustments.	$1.79B	$1.82B	$2.64B	$6.93B	$14.92B	$44.66B
EV / SalesHow many dollars investors pay per dollar of sales.	60.93x	51.54x	227.71x	0.00x	0.00x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-9.96x	-7.61x	-6.13x	-11.76x	-13.68x	-26.34x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.23	0.41	1.41	0.69	0.21	0.10

Returns + ROCE gauge

ROCE latest

-41.0%

Prev year -57.3%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-31.0%	-36.3%	-23.9%	-26.5%	-69.3%	-96.4%
ROAProfit generated from total assets.	-25.4%	-30.6%	-21.2%	-23.5%	-48.0%	-40.9%
ROICReturn generated on invested operating capital.	-27.7%	-33.4%	-22.9%	-25.2%	-54.8%	-43.7%
ROCEOperating return on long-term capital used.	-27.7%	-34.4%	-25.4%	-28.8%	-57.3%	-41.0%
Earnings YieldEarnings as a percentage of market value.	-10.2%	-12.9%	-13.4%	-8.2%	-7.5%	-4.0%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-153.70M	$-235.22M	$-358.00M	$-567.74M	$-889.50M	$-1.53B
FCFECash flow available to equity holders after debt flows.	$-153.71M	$-235.22M	$-358.30M	$-567.74M	$-669.52M	$-856.55M
FCF YieldFree cash flow divided by market capitalization.	-8.4%	-12.2%	-11.0%	-7.7%	-6.0%	-3.5%
Income QualityHow well accounting earnings are backed by cash flow.	0.79	0.90	0.80	0.93	0.79	0.71
Capex / OCFShare of operating cash flow spent on capital expenditures.	-4.4%	-4.8%	-2.2%	-1.8%	-1.8%	-0.7%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	73.6d	48.2d	39.5d	0.0d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	0.0d	0.0d	0.0d	0.0d	1424.4d	3493.9d
Operating CycleTime from buying inventory to collecting receivables.	73.6d	48.2d	39.5d	0.0d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	73.6d	48.2d	39.5d	0.0d	-1424.4d	-3493.9d

Snapshot

Latest / TTM: —

Market Cap

$44.83B

ROE

-96.4%

FCF Yield

-3.5%

Current Ratio

11.38

Upstream

Contract Manufacturing Organizations (CMOs)Contract Research Organizations (CROs)Lonza Group AGSIX:LONNThermo Fisher Scientific Inc.NYSE:TMOActive Pharmaceutical Ingredient (API) SuppliersChemical and Biological Reagent Suppliers

Downstream

Patients with RAS-addicted cancersRoyalty Pharma plcNASDAQ:RPRX Tango Therapeutics, Inc.NASDAQ:TNGX Summit Therapeutics Inc.NASDAQ:SMMT Amgen Inc.NASDAQ:AMGN Bristol Myers Squibb CompanyNYSE:BMYBreak Through Cancer FoundationSanofi SANASDAQ:SNYSpecialty Pharmacy Partners (to be established)Specialty Distributor Partners (to be established)

Proxies

Mirati TherapeuticsNASDAQ:MRTX Novartis AGNYSE:NVS Revolution Medicines (prior Sanofi partnership model)NASDAQ:RVMD Royalty Pharma plcNASDAQ:RPRX Amgen Inc.NASDAQ:AMGN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Revolution Medicines, Inc.

Key Metrics of RVMD

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of RVMD

Upstream

Downstream

Proxies

Key Metrics of RVMD

Key Metrics

Valuation trend

Returns + ROCE gauge

Cash flow quality

Operating efficiency

Snapshot

Supply Chain of RVMD

Upstream

Downstream

Proxies